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A B S T R A C T
In accordance with the goal of the World Health Organization Regional Oﬃce for Europe, the Italian National
Measles and Rubella Elimination Plan aimed to interrupt indigenous measles transmission in Italy by the end of
2015. However, from 2013 to 2015, Italy experienced high measles burden with 4902 measles cases (49.3%
laboratory-conﬁrmed) reported to the enhanced measles surveillance system (cumulative incidence in the
triennium reference period: 2.4/100,000 population). The measles elimination goal was not reached.
Laboratory surveillance of measles circulating genotypes is performed by the Measles and Rubella National
Reference Laboratory (NRL) at the Italian National Institute of Health (Istituto Superiore di Sanità − ISS), in
Rome. Samples received from 1 January 2013–31 December 2015 were analysed. Those positive for measles
genome by molecular tests were sequenced and phylogenetically analysed. Phylogenetic analysis performed by
NRL identiﬁed that genotypes D4 and D8 were endemic and co-circulated in 2011–2013: study results show that
genotype D4 disappeared during 2013. Sporadic cases were associated to genotype B3 during 2011–2013, which
became endemic in Italy during 2014 and co-circulated with D8 until 2015. Sporadic cases were found belonging
to genotypes D9 and H1 all over the period in exam. Similar trend has been observed in European WHO Region.
1. Introduction
Measles virus (MV), member of the Paramyxoviridae family, is a
leading cause of mortality among young children worldwide, with an
estimated 134,200 deaths due to measles-related complications in 2015
(WHO, 2017a). Although measles is a highly contagious viral disease,
its transmission can be easily prevented by vaccination.
In order to reach measles elimination, a very high coverage of at
least 95% for two doses of vaccine is needed (WHO, 2012a). A
monovalent measles vaccine was introduced in Italy in 1976. This
was replaced in 1993 by the combined measles-mumps-rubella (MMR)
vaccine, given as a single dose at 13–15 months of age, but only since
1999, the vaccination with MMR has been included in the national
immunization program. Currently, a ﬁrst dose of MMR vaccine is
⁎ Corresponding author at: Department of Infectious Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
E-mail addresses: fabio.magurano@iss.it (F. Magurano), Melissa.baggieri@iss.it (M. Baggieri), Antonietta.ﬁlia@iss.it (A. Filia), martina.delmanso@iss.it (M. Del Manso),
tiziana.lazzarotto@unibo.it (T. Lazzarotto), Antonella.amendola@unimi.it (A. Amendola), pierlanfranco.dagaro@burlo.trieste.it (P. D’Agaro), maria.chironna@uniba.it (M. Chironna), 
Filippo.ansaldi@unige.it (F. Ansaldi), s.iannazzo@sanita.it (S. Iannazzo), paola.bucci@iss.it (P. Bucci), Antonella.marchi@iss.it (A. Marchi), loredana.nicolett@iss.it (L. Nicoletti).
1 (in addition to the authors) consisted of: Maraglino FP (Ministry of Health, DG for Prevention, V Oﬃce, Rome, Italy); Villari P (National Veriﬁcation Committee, Rome, Italy); Declich 
S, Rota MC, Bella A (National Institute of Health, Rome, Italy); Baldanti F, Piralla A, (IRCCS Policlinico San Matteo Foundation, Pavia, Italy); Bianchi S, Tanzi E (University of Milan, 
Italy); Bordi L, Lalle E (National Institute for Infectious Diseases “Lazzaro Spallanzani”, Rome, Italy); Piccirilli G (University of Bologna, Italy); Marinelli K (United Hospital of Ancona, 
Italy); Santon D (University of Trieste, Italy); Orsi A (University of Genoa, Italy); Morea A (University of Bari, Italy).
2recommended at the age of 12–15 months and a second dose at 5–6
years (Filia et al., 2013). National administrative vaccine coverage for
the ﬁrst dose of MMR vaccine in children at two years of age, decreased
from 90.4% in 2013–86.7% in 2014 and 85.3 in 2015 due to the
economic crisis and a completely discredited health scare linking the
MMR jab to autism.
The World Health Organization (WHO) European Regional
Committee set 2015 as target date for the elimination of measles
(WHO, 2010): regional elimination can be declared after 36 or more
months of the absence of endemic measles or rubella in all Member
States (Mankertz et al., 2011).
Currently, eliminating measles and rubella is a core goal of the
European Vaccine Action Plan 2015–2020.
Based on a country-by-country assessment, during its ﬁfth meeting
in 2016, the European Regional Veriﬁcation Commission for Measles
and Rubella Elimination (RVC) concluded that based on reports
submitted, at the end of 2015, endemic measles transmission had been
interrupted in 37 of the 53 Member States (70%). Twenty- four Member
States (45%) provided evidence to demonstrate the elimination of
endemic transmission of measles for at least 36 months; further 13
Member States (25%) provided evidence for the interruption of measles
transmission for a period of less than 36 months. Fourteen Member
States (26%) were considered by the RVC to remain endemic for
measles transmission, including Italy (WHO, 2017b).
Fourteen Member States (26%) were considered by the RVC to
remain endemic for measles transmission, and 16 (30%) were con-
sidered to remain endemic for rubella transmission. Fourteen Member
States (26%) were considered to remain endemic for both measles and
rubella. WHO’s plan to eliminate measles seeks to improve measles
surveillance systems throughout the world by WHO Measles and
Rubella Laboratory Network (Mulders et al., 2016), in order to detect
all clinical measles cases and to investigate thoroughly every single
cases and outbreaks. In Italy, the surveillance of measles consists of a
case reporting system based on epidemiological investigation on cases
clinically consistent with measles supported by laboratory conﬁrma-
tion. Analysis of samples for laboratory conﬁrmation of infection is
performed by the National Reference Laboratory (NRL) at the National
Institute of Health and by Subnational Reference Laboratories (SRLs)
not WHO accredited. The reporting and laboratory surveillance system
has been previously described (Magurano et al., 2015).
Virus surveillance and genetic characterization of circulating viruses
are important tools for regional and global control eﬀorts. Within the
WHO’s goal to eliminate the virus, the NRL plays a key role in
supporting cases ascertainment in Italy, conﬁrming outbreaks/cases
and determining MV circulating genotypes.
This report describes the Italian virological surveillance for measles
in the triennium 2013–2015.
2. Material and methods
2.1. Epidemiological data
Since 1934, measles disease has been statutorily notiﬁable in Italy.
In 2007, an enhanced surveillance system was introduced which
requires physicians to report all suspected measles cases to the local
health authorities within 12 h (Italian Ministry of Health, 2007).
For each suspected case, the local health authorities are required to
carry out an epidemiological investigation, to obtain specimens for
laboratory conﬁrmation and genotyping, and complete a standard
measles notiﬁcation process on the online database of the National
Fig. 1. Measles cases by month of rash onset (A) and incidence by age group (B), Italy, 2013–2015.




Urine, oral ﬂuid (OF) and dried blood samples were collected after
onset of rash from suspected measles cases according to WHO recom-
mendations (WHO, 2007). Serological and molecular diagnosis were
performed on these samples as previously described (Magurano et al.,
2015). Sequences were obtained amplifying by RT-PCR a fragment of
the carboxyl-terminal coding region of the N gene, including the 450 bp
recommended for genotyping. Sequences provided by SRLs were also
included in this study.
Sequence data were analyzed by BioEdit (version 7.0). Bayesian
information criterion (BIC) was used to determine the model of
nucleotide substitution that best ﬁt the data using the selection tool
available in MEGA6 (Tamura et al., 2013). The model that best ﬁt the
data was the Kimura 2-parameter (k2) model. Phylogenetic analyses
were performed using MEGA version 6 by the Kimura 2 (K2) method by
1000 resampling. MV strains were named as designated by WHO
(WHO, 2012b). The sequences reported in this article have been
deposited into the WHO’s MeaNS database (Rota et al., 2011).
3. Results
From January 2013 to December 2015, 4902 cases were reported in
Italy. Of these 2416 were laboratory-conﬁrmed (Fig. 1A) by serological
and/or molecular methods performed on dried blood spots and urine/
OF samples, respectively.
The cumulative incidence in the three-year period was 2.4 cases per
100,000 population, the data were supported by statistical analysis
(4.1, 2.7 and 0.4 cases per 100,000 in 2013, 2014 and 2015,
respectively).
Fig. 1B shows the age group distribution and incidence of measles
cases in Italy for the period 2013–2015. The highest incidence was
found in the age group 0–4 years followed by the age group 15–39
years, these groups present the higher number of measles-susceptibles.
Median age of cases was 22 years (range: 0–83 years).
Overall, samples were collected from 2848 suspected measles cases
and for 359 of these the vaccination was available, 245 and 79 were
vaccinated with a single and two doses, respectively. All the samples
were tested either by serological or molecular methods. PCR-positive
samples coming from the regions where measles cases were reported
were sequenced. A total of 484 sequences from diﬀerent Italian regions
were phylogenetically analysed by the NRL: 167 in 2013, 260 in 2014
and 57 in 2015. Fig. 2A shows the genotypes distribution by year.
Sequence analysis identiﬁed the co-circulation of genotype D4 and
D8 in the year 2013 similarly to 2011 and 2012 (data not shown). No
cases were found to belong to genotype D4 in 2014, when the genotype
D8 circulated together with genotype B3. Sporadic cases belonged to
genotypes D9 and H1 during the years 2013 and 2014. The Italian trend
of MV genotypes distribution by each year is shown in Fig. 2A.
3.1. D4
NRL’s results showed that D4 was endemic in 2010 (Baggieri et al.,
2014) and continued to be endemic until the ﬁrst half of 2013. The
phylogenetic tree (Fig. 3A) shows that all D4 MV strains of 2013
grouped into 2 diﬀerent clusters. Each cluster shows a 100% identity
with a “WHO single named variant”: the Manchester (MVs/Manches-
ter.GBR/10.09/) and the Iasi (MVs/Iasi.ROU/12.12/) variants.
Genotype D4 was not observed in 2014, and only 3 sporadic cases
were identiﬁed in 2015. Epidemiological data revealed that two of
these cases (identiﬁed in the province of Parma) were imported from
India.
3.2. D8
Beside genotype D4, D8 circulated in Italy during 2011 and 2012
(Magurano et al., 2015) and increased in 2013 with a rate of presence of
83.8% (140/167). During 2014, D8 circulated with genotype B3, with
88 cases leading the percentage to 33.8% (88/260). In 2015 genotype
D8 was responsible of 16 out of 57 (28%) cases characterized.
The phylogenetic tree (Fig. 4A) shows that all D8MV strains in 2013
grouped into 3 diﬀerent cluster. Each cluster shows a 100% identity
with a WHO named variant: the Taunton (MVs/Taunton.GBR/27.12/),
the Frankfurt-Main (MVs/Frankfurt-Main.DEU/17.11/) and the Villu-
puram (MVi/Villupuram.IND/03.07/) variants.
Five clusters with ﬁve related WHO named variant were identiﬁed
in 2014 (Fig. 4B): the Taunton, the Frankfurt Main, Hulu Langat (MVi/
HuluLangat.MYS/26.11/), Rostov on Don (MVs/Rostov on Don.RUS/
47.13/2) and Villupuram. One unnamed variant was also identiﬁed.
Data of 2014 on the circulation of genotype D8 in Northern Italy
(Lombardy) have been reported (Amendola et al., 2017).
In 2015 two main clusters of D8 were identiﬁed: one of these
showed a 100% identity with the WHO variant “Rostov on Don” (MVs/
Rostov on Don.RUS/47.13/2), and the second showed an identity of
100% with the “Villupuram” WHO variant.
In summary, “Taunton” was the most representative variant during
2013 − 2014, as it has been identiﬁed from 39 and 28 cases,
respectively. Strains belonging to this variant circulated in the
Lombardy, Piedmont, Friuli-Venezia Giulia, Veneto, Trentino-Alto
Adige, Marche, Emilia-Romagna, Tuscany, Umbria, Abruzzo,
Campania and Apulia Italian regions in 2013 and in Lombardy,
Piedmont, and Calabria in 2014. In the same years, the “Frankfurt-
Main” variant was identiﬁed in Lombardy, Veneto, Friuli-Venezia
Giulia, Trentino-Alto Adige, Piedmont, Tuscany and Marche in 2013
and only in Lombardy in 2014. The “Villupuram” variant represents the
only D8 variant ever identiﬁed during all the triennium 2013–2015 (in
Veneto, Emilia-Romagna, Abruzzo, Basilicata and Apulia in 2013, in
Fig. 2. Italian (A) and European (B) measles genotypes trend from 2013 to 2015.
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4Veneto in 2014 and in Trentino-Alto Adige in 2015). Three more WHO
measles variants circulated in 2014: Hulu Langat and an unnamed
variant were identiﬁed in Lombardy and Rostov on Don variant in
Friuli-Venezia Giulia (Fig. 4C). Moreover, the latter was the most
representative variant in 2015, being identiﬁed in Trentino-Alto Adige,
Friuli-Venezia Giulia, Umbria and Sardinia, and involved in an out-
break occurred at an international dog show in Slovenia (MVs/Nova
Gorica.SVN/47.14/) in November 2014 (Kalaycioglu et al., 2016;
Grgič-Vitek et al., 2015). The WHO named variants described above
were reported in the reviewed period in other European countries (Filia
et al., 2015; Santibanez et al., 2015; Rasmussen et al., 2015).
3.3. B3
B3 circulated throughout the period 2013–2015: it was identiﬁed
from 5 cases in 2013, while the genotype co-circulated with genotype
Fig. 3. Neighbour-joining tree for nucleotide sequences of MV strains belonging to genotype D4 (A) and genotype B3 (B). Number in brackets indicate the total number of identical
sequences identiﬁed in the same province by the same week.
Fig. 4. Neighbour-joining trees for nucleotide sequences of MV strains belonging to genotype D8. A–C refer to the years 2013, 2014 and 2015, respectively. Numbers in brackets indicate
the total number of identical sequences identiﬁed in the same province by the same week.
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5D8 and was identiﬁed in 164 cases in 2014. In 2015, genotype B3 was
responsible of 38 out of 57 (66.7%) characterized cases.
The 8 sequences identiﬁed in 2013 (Fig. 3B) were similar to each
other and to those already circulating in Northern Italy in 2010 (MVs/
Genoa.ITA/32.10/2, GenBank KJ573572). These strains all belong to
the variant “Harare” (MVi/Harare.ZWE/38.09/).
During 2014, B3 was the most frequently identiﬁed genotype, with
a percentage of 63.1% (164/260). B3 strains belonged to 3 main WHO
named variants (Tonbridge, Harare, Dakar) and to a WHO unnamed
variant (proposed as “Ústí nad Labem”), including that responsible for a
cruise ship outbreak occurred at the beginning of the year (Lanini et al.,
2014). The circulation of these WHO variants has been illustrated (Filia
et al., 2015; Magurano et al., 2016; Nic Lochlainn et al., 2016). In 2015,
genotype B3 continued to be the most frequent genotype with the
variants: “Harare” (MVi/Harare.ZWE/38.09/) in the Veneto, Friuli
Venezia Giulia, Apulia, Lombardy and Emilia Romagna regions;
“Kansas” (MVs/Kansas.USA/1.12/) in Lombardy, Liguria, Trentino Alto
Adige, Tuscany, and Apulia. Two more unnamed variants were
identiﬁed: one in Northern Italy (MVs/Como.ITA/32.15/) was respon-
sible for an outbreak occurred in the Roma/Sinti population with
transmission in the nosocomial setting, described by Filia et al. (2016);
the second was identiﬁed in Southern Italy (MVs/Napoli.ITA/45.15/).
3.4. D9
Four sequences belonging to genotype D9 were identiﬁed in 2013
and 1 in 2014 (Fig. 5). Two out of four sequences of 2013 (MVs/
Monza.ITA/45.13/) were 100% identical to each other and to the
strains identiﬁed in Australia (GenBank KF802423) in the same period,
belonged to the WHO named variant “Yamanashi” (MVs/Yamana-
shi.JPN/51.12/). Anyway, no epidemiological data are available to
determine possible routes of importation for these strains in Italy. One
sequence identiﬁed in 2013 (MVs/Varese.ITA/33.13/) showed 99% of
identity with strains circulating in USA (GenBank JX308263), Turkey
(Kalaycioglu et al., 2013) and Malaysia (GenBank JQ978702) during
2012. Epidemiological data conﬁrmed that this strain was imported
from Australia, where the patient had traveled.
A fourth strain identiﬁed in 2013 (MVs/Bologna.ITA/41.13/) was
99% similar to that identiﬁed in Australia (GenBank KF802423) in the
same period, and epidemiological data conﬁrmed the importation of
this strain from Indonesia.
The unique D9 sequence identiﬁed in 2014 (MVs/Bolzano.ITA/
43.14/) was identical to the strain MVs/Feldkirch.AUT/42.14/(Means
67972) identiﬁed in the same year in Austria. Epidemiological data are
not enough to establish a route of importation from Austria.
3.5. H1
Genotype H1 was identiﬁed in four measles cases during an
outbreak reported in 2014 in Central Italy (Ancona, Marche) (Fig. 5).
The H1 sequences were identical to a strain identiﬁed in New Zealand
in the same year (MVs/Wellington.NZL/8.14/, GenBank KJ619489).
Epidemiological data available for these cases was insuﬃcient to
establish the route of importation of infection.
4. Discussion and conclusions
Phylogenetic analysis of wild-type MV showed that the genotypes
D4 and D8 were endemic in Italy in 2013. Genotype D8 circulated all
over the triennium, whereas D4 circulated up to the ﬁrst half of 2013
and sporadic cases were detected in 2015.
Sporadic MV strains belonging to genotype B3 were detected during
2013, afterwards the genotype became endemic in the next biennium
2014–2015. Sporadic cases of D9 and H1 were identiﬁed in 2013 and
2014, probably due to importation from Asian countries where these
genotypes are endemic, but there were not epidemiological data to
support this hypothesis for all the cases reported. Likewise, one B3
strain (MVs/Modena.ITA/21.13/, Harare variant) was probably was
probably imported from Africa and introduced in Italy in 2013. The
circulation of genotypes in the European WHO Region (data from
MeaNS) followed a similar trend with prevalence of D8 and B3
(Fig. 2B).
Virological surveillance represents a fundamental tool to document
the interruption of the transmission of endemic measles and needs to be
further strengthened in Italy. Timely and accurate laboratory diagnosis,
including molecular characterization of circulating measles strains, is
essential to identify imported viruses, deﬁne import-related outbreaks
and understand transmission patterns. Currently, local epidemiological
investigation on the outbreak is inadequate. As a consequence, even
though the work of NRL/SRLs laboratories allowed to identify MV
genotypes responsible for several Italian outbreaks in the triennium, the
rate of genomic characterization above the total number of outbreaks
reported (which is one of the indicators to evaluate the performance of
the national laboratory national system) is far from 80% requested by
WHO (10% in 2013, 43.1% in 2014 and 40% in 2015). All these data
show that Italy is far from measles elimination.
In order to increase performance level requested by WHO, including
timeliness and completeness of data, in March 2017 a sub-national
network of accredited labs for measles and rubella (MoRoNet) coordi-
nated by the NRL was formalized (Magurano et al., 2017).
Moreover, Italy is far from the vaccination coverage of at least 95%
with two doses of measles vaccine needed to interrupt the circulation of
MV and strategies should be reinforced to address the susceptibility to
measles of unvaccinated young adults and other population groups.
In conclusion, as recommended by WHO Italy needs to renew
political commitment and improve its National Surveillance System to
reach the goal of measles elimination (Adamo et al., 2017). Main
challenges include low population immunity, consistently low and ever
decrease routine vaccination coverage, a complex surveillance system
with suboptimal sensitivity and insuﬃcient engagement of proﬁcient
laboratory in the surveillance system, in addition to the WHO-accre-
dited laboratory.
This paper describes measles cases reported to the Italian national
measles surveillance system between 1st January 2013 and 31st
December 2015, and discusses some of the priorities for reaching
measles elimination. Since measles elimination in the WHO European
Region is a public health priority, it is crucial to share information with
all the actors involved in the European public health and underline the
severity of measles even in industrialized countries. Further eﬀort and
more investments will be needed to allow Italy to become one of the
countries that have interrupted endemic measles transmission.
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